Poplar Therapeutics, incorporated in 2024 and based in Cambridge, Massachusetts, is focused on creating a new class of anti-IgE therapies that aim to rapidly drive IgE levels toward zero. Its lead candidate, PHB-050, employs a triple-action mechanism to block IgE binding to mast cells, quickly clear circulating IgE, and inhibit further IgE production. The drug is now in a Phase 1 clinical trial targeting food allergy, with data expected to demonstrate safety, pharmacokinetics, and speed of IgE reduction. Management plans to use forthcoming data to guide Phase 2 studies across multiple atopic conditions, including asthma and atopic dermatitis. Poplar estimates that more than seven million patients with atopic diseases have high IgE levels, half of whom with food allergy are poorly served by existing therapies. The company’s total Series A financing now stands at $95 million, providing resources to advance PHB-050 through at least Phase 2 trials.

Total raised

$95M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2026